Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Barinthus Biotherapeutics plc (BRNS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BRNS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -56.95% | Avg. Invested days 17 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 51.95M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 3 | Beta -0.72 | 52 Weeks Range 0.64 - 2.91 | Updated Date 08/15/2025 |
52 Weeks Range 0.64 - 2.91 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.36 | Actual -0.52 |
Profitability
Profit Margin - | Operating Margin (TTM) -360.87% |
Management Effectiveness
Return on Assets (TTM) -21.35% | Return on Equity (TTM) -53.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -22318612 | Price to Sales(TTM) 3.47 |
Enterprise Value -22318612 | Price to Sales(TTM) 3.47 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA -6.67 | Shares Outstanding 40718200 | Shares Floating 35406943 |
Shares Outstanding 40718200 | Shares Floating 35406943 | ||
Percent Insiders 14.32 | Percent Institutions 44.51 |
Upturn AI SWOT
Barinthus Biotherapeutics plc
Company Overview
History and Background
Barinthus Biotherapeutics plc (formerly Vaccitech) is a biopharmaceutical company focused on developing novel T cell immunotherapeutics designed to treat and prevent infectious diseases, autoimmunity, and cancer. Founded in 2010 as a spin-out from the University of Oxford, the company has evolved from a vaccine development platform to a broader immunotherapy focus, recently rebranding as Barinthus Biotherapeutics.
Core Business Areas
- Infectious Diseases: Development of T cell immunotherapeutics for chronic infectious diseases like hepatitis B virus (HBV).
- Autoimmunity: Development of T cell immunotherapeutics for autoimmune diseases such as Celiac Disease.
- Oncology: Development of T cell immunotherapeutics for various cancers, focusing on targeting tumor-associated antigens.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. Details are available on the company's investor relations website.
Top Products and Market Share
Key Offerings
- VTP-300 (HBV): An immunotherapeutic candidate for the treatment of chronic hepatitis B virus infection. Currently in clinical development (Phase 1/2). Competitors include companies developing direct-acting antivirals and other immunotherapies for HBV, such as Gilead Sciences (GILD) and Vir Biotechnology (VIR). Market share data not yet available due to development stage.
- VTP-15269 (Celiac Disease): An immunotherapeutic candidate for Celiac Disease. Currently in clinical development (Phase 1). Competitors include companies developing gluten degrading enzymes and other immunomodulatory agents for Celiac Disease, such as Amgen (AMGN) and Provention Bio (acquired by Sanofi (SNY)). Market share data not yet available due to development stage.
- VTP-850 (Prostate Cancer): An immunotherapeutic candidate for Prostate Cancer. Currently in clinical development (Phase 1/2a). Competitors include companies developing hormonal therapies, chemotherapy, and other immunotherapies for Prostate Cancer such as Johnson & Johnson (JNJ), Pfizer (PFE), and Bristol Myers Squibb (BMY). Market share data not yet available due to development stage.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. The immunotherapy segment is rapidly growing, driven by advances in understanding the immune system and its role in disease. Investment in immunotherapy is a main focus for many companies.
Positioning
Barinthus Biotherapeutics is positioned as a T cell immunotherapy company with a focus on developing novel treatments for infectious diseases, autoimmunity, and cancer. The company's platform technology aims to stimulate T cell responses to target specific antigens.
Total Addressable Market (TAM)
The total addressable market for immunotherapies across infectious diseases, autoimmunity, and cancer is estimated to be in the hundreds of billions of dollars annually. Barinthus Biotherapeutics aims to capture a significant portion of this market by developing differentiated and effective T cell immunotherapies.
Upturn SWOT Analysis
Strengths
- Novel T cell immunotherapy platform
- Experienced management team
- Diverse pipeline of product candidates
- Strong scientific foundation based on University of Oxford technology
- Strategic collaborations with leading research institutions
Weaknesses
- Early-stage clinical development risks
- High R&D costs and lengthy development timelines
- Dependence on successful clinical trial outcomes
- Competition from larger pharmaceutical companies
- Limited commercial infrastructure
Opportunities
- Expansion of pipeline into new disease areas
- Strategic partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approval
- Increasing demand for immunotherapies
- Advancements in T cell biology and immunotherapy technologies
Threats
- Clinical trial failures
- Regulatory delays or rejections
- Competition from established therapies
- Patent infringement or challenges
- Economic downturn affecting R&D investment
Competitors and Market Share
Key Competitors
- GILD
- VIR
- AMGN
- SNY
- JNJ
- PFE
- BMY
Competitive Landscape
Barinthus Biotherapeutics faces competition from larger pharmaceutical companies with established market presence and resources. The company's competitive advantage lies in its novel T cell immunotherapy platform and focused approach to specific disease areas.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage. Growth potential is linked to successful clinical outcomes and partnerships.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates are available from financial data providers.
Recent Initiatives: Recent initiatives include rebranding, pipeline advancement, and strategic collaborations.
Summary
Barinthus Biotherapeutics is an early-stage biotech company focused on T cell immunotherapies. While its pipeline shows promise, the company faces significant risks associated with clinical development and competition from larger players. Successful clinical trial outcomes and strategic partnerships are crucial for its future growth. The company is still considered high risk as of current.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Barinthus Biotherapeutics plc website
- SEC filings
- Financial data providers
- Industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Barinthus Biotherapeutics plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-04-30 | CEO, Director & Principal Financial Officer Mr. William J. Enright MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.barinthusbio.com |
Full time employees 105 | Website https://www.barinthusbio.com | ||
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.